Acute myeloid leukemia of mixed megakaryocytic and erythroid origin following chemotherapy for T-cell lymphoblastic lymphoma.
Department of Laboratory Medicine, The Catholic University of Korea, Seoul, Korea.
Woori
W
Jang
Myungshin
M
Kim
Jae Wook
JW
Lee
Nack-Gyun
NG
Chung
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D041905:Erythroid Cells / Q000473:pathology*; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D060828:Induction Chemotherapy; D015470:Leukemia, Myeloid, Acute / Q000473:pathology*; D008297:Male; D008479:Mediastinal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008533:Megakaryocytes / Q000473:pathology*; D008942:Mitoxantrone / Q000008:administration & dosage; D016609:Neoplasms, Second Primary; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology*; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D014750:Vincristine; D003907:Dexamethasone; D008942:Mitoxantrone; D001215:Asparaginase; D015255:Idarubicin; D003630:Daunorubicin